Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Cephalon Opts To Buy Ception

by Lisa M. Jarvis
March 1, 2010 | A version of this story appeared in Volume 88, Issue 9

After reporting positive Phase II clinical results for its asthma treatment reslizumab, Ception Therapeutics is being acquired by Cephalon for $250 million. Cephalon paid $100 million for an option to buy Ception in early 2009 with an eye to expanding its portfolio beyond small molecules. Reslizumab is a monoclonal antibody against interleukin-5, a cell-signaling molecule involved in the growth and movement of inflammatory white blood cells.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.